Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence

Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide b...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of internal medicine Vol. 35; no. 3; pp. 498 - 513
Main Authors Choi, Hong-Mi, Shin, Mi-Seung
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Association of Internal Medicine 01.05.2020
대한내과학회
Subjects
Angiotensin Receptor Antagonists - adverse effects
angiotensin receptor inhibitor
Antihypertensive Agents
heart failure
Heart Failure - diagnosis
Heart Failure - drug therapy
Humans
Neprilysin
Receptors, Angiotensin
Review
내과학
Heart failure
Angiotensin receptor inhibitor
Neprilysin
Online AccessGet full text

Cover

More Information
Summary:Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide breakdown in combination with hindering the renin-angiotensin system in HF patients with a reduced ejection fraction. Subsequent large-scale randomized trials have evaluated angiotensin receptor-neprilysin inhibitor in HF patients with acute decompensation or with preserved ejection fraction. The post hoc analyses are being conducted as well. This review summarizes the recent evidence of sacubitril/ valsartan regarding patient-centered outcomes, based on randomized controlled trials and their associated studies.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This paper was contributed by The Korean Society of Heart Failure.
ISSN:1226-3303
2005-6648
DOI:10.3904/kjim.2020.105